High expression of PIG11 correlates with poor prognosis in gastric cancer

Abstract

P53-induced gene 11 (PIG11) is an early transcription-related target of p53 that is involved in cell apoptosis and tumor development. However, its biological function in gastric cancer (GC) tissues and relationship with the prognosis of patients with GC have remained elusive. In the present retrospective study, 60 fresh and 790 paraffin-embedded samples of GC were obtained from the Affiliated Hospital of Nantong University (Nantong, China) with complete clinical data from all patients. Reverse transcription-quantitative PCR and tissue microarray-immunohistochemical analysis were used to determine the expression of PIG11 in the respective GC tissues. A receiver operating characteristic (ROC) curve was plotted to determine the diagnostic utility of PIG11 expression in GC. Furthermore, three online databases, including Gene Expression Profiling Interactive Analysis (GEPIA), Oncomine and Kaplan-Meier plotter, were used for bioinformatics analysis of PIG11. PIG11 expression in GC tissues was high, which was positively correlated with invasive depth (P<0.001), lymph node metastasis (P<0.001), distant metastasis (P=0.019), TNM staging (P<0.001) and carcinoembryonic antigen in serum (P<0.001), and negatively associated with the overall survival of patients with GC. The ROC curve analysis suggested that based on PIG11 expression, it was possible to distinguish GC tissues from adjacent normal tissues (P<0.0001) with a sensitivity and specificity of 81.67 and 76.67%, respectively. In addition, Cox logistic regression analysis demonstrated that high PIG11 expression is a novel biomarker for unfavorable prognosis of patients with GC. Furthermore, the results obtained from the GEPIA database indicated that PIG11 expression is correlated with TNF, carcinoembryonic antigen related cell adhesion molecule 5, phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha, VEGFA and kinase insert domain receptor. Therefore, PIG11 expression may be associated with the malignancy of GC and may serve as a potential diagnostic and prognostic biomarker for GC.

Glis1 and oxaloacetate in nucleus pulposus stromal cell somatic reprogramming and survival

“…In adult stem cells, reduced P53 aids in reprogramming ( Marion et al, 2009 ; Maeso-Alonso et al, 2021 ), whereas P73 aids in controlling cell cycle progression and plays additional rolls in cell–adhesion and cell–ECM interactions ( Maeso-Alonso et al, 2021 ). A positive correlation between P53 , P73 , and Ki67 transcript levels was noted in all cell types, with higher levels in IVD over FAT cells, whereas P53-induced protein 11 transcripts ( TP53I11 , Pig11 ) ( Gu et al, 2021 ) showed a negative correlation and were downregulated in IVD over FAT cells. Perp encoding an effector in the TP53-dependent apoptotic pathway was also downregulated in NP over FAT cells in 2D culture.…”

NPM1 is a diagnostic and prognostic biomarker associated with the clinicopathological characteristics of gastric cancer

“…Immunohistochemical staining. We used immunohistochemical staining analysis according to the [29]. For antigen retrieval, the TMA slides are dewaxed, rehydrated and boiled in a pressure pot with sodium citrate buffer (pH 6.0).…”

An integrated analysis revealing the angiogenic function of TP53I11 in tumor microenvironment

“…In vitro experiments have indicated the suppression of epithelial-mesenchymal transition and metastasis in breast cancer cells [ 12 ] and enhanced apoptosis in liver cancer cells [ 10 , 11 ]. Conversely, other studies have suggested that TP53I11 may play a role in promoting the development and progression of certain cancers [ 9 , 14 ]. In a recent bioinformatics study, it was found that breast cancer has a considerably elevated expression of TP53I11, and patients with low levels of expression tend to have a better survival rate [ 14 ].…”

“…TP53I11 was one of the genes identified in the study. Studies have shown that TP53I11 is primarily expressed in the mammary gland, liver, and gastrointestinal tract, as well as in the corresponding cancer tissues [ 9 ]. Research has also linked TP53I11 to the development and progression of various types of tumors, including non-small cell lung, breast, liver, and gastric cancers.…”

“…In a recent bioinformatics study, it was found that breast cancer has a considerably elevated expression of TP53I11, and patients with low levels of expression tend to have a better survival rate [ 14 ]. High levels of TP53I11 have also been found to be prevalent in gastric cancer and have been shown to be strongly correlated with increased invasive depth, lymph node metastasis, distant metastasis, advanced staging [tumor (T), nodes (N), and metastases (M) (TNM)], and decreased overall survival in patients with gastric cancer [ 9 ]. Elevated levels of TP53I11 have also been linked to elevated serum levels of carcinoembryonic antigens [ 9 ].…”